A oxygen transfer agent useful for the oxidative dehydrogenation of saturated hydrocarbons includes at least one mixed oxide derived from manganese or compounds thereof, as well as a promoter, such as tungsten and/or phosphorus. The oxygen transfer agent may also include an alkali metal or compounds thereof, boron or compounds thereof, an oxide of an alkaline earth metal, and an oxide containing one or more of one or more of manganese, lithium, boron, and magnesium. A reactor is at least partially filled with the oxygen transfer agent in the form of a fixed or circulating bed and provides an unsaturated hydrocarbon product, such as ethylene and/or propylene. The oxygen transfer agent may be regenerated using oxygen.

Provided is a method for preparing a diol. In the method, a saccharide and hydrogen as raw materials are contacted with a catalyst in water to prepare the diol. The employed catalyst is a composite catalyst comprised of a main catalyst and a cocatalyst, wherein the main catalyst is a water-insoluble acid-resistant alloy; and the cocatalyst is a soluble tungstate and/or soluble tungsten compound. The method uses an acid-resistant, inexpensive and stable alloy needless of a support as a main catalyst, and can guarantee a high yield of the diol in the case where the production cost is relatively low.

Provided is a method for preparing a diol. In the method, a saccharide and hydrogen as raw materials are contacted with a catalyst in water to prepare the diol. The employed catalyst is a composite catalyst comprised of a main catalyst and a cocatalyst, wherein the main catalyst is a water-insoluble acid-resistant alloy; and the cocatalyst is a soluble tungstate and/or soluble tungsten compound. The method uses an acid-resistant, inexpensive and stable alloy needless of a support as a main catalyst, and can guarantee a high yield of the diol in the case where the production cost is relatively low.

The present invention relates to: a catalyst for glycerin dehydration; a preparation method therefor; and an acrolein preparation method using the catalyst. According to one embodiment of the present invention, the catalyst is used in glycerin dehydration so as to exhibit high catalytic activity, a high yield and high acrolein selectivity, and has a characteristic in which carbon is not readily deposited, thereby having a long lifetime compared with that of a conventional catalyst.

The present invention relates to: a catalyst for glycerin dehydration; a preparation method therefor; and an acrolein preparation method using the catalyst. According to one embodiment of the present invention, the catalyst is used in glycerin dehydration so as to exhibit high catalytic activity, a high yield and high acrolein selectivity, and has a characteristic in which carbon is not readily deposited, thereby having a long lifetime compared with that of a conventional catalyst.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

The problem to be solved by the present invention is to provide a good NOx selective reduction catalyst. To solve the problem is a NOx selective reduction catalyst containing a composite oxide of Ti, Ce, W, and P or S.

The problem to be solved by the present invention is to provide a good NOx selective reduction catalyst. To solve the problem is a NOx selective reduction catalyst containing a composite oxide of Ti, Ce, W, and P or S.

The present invention relates to heterogeneous acid catalysts comprising or consisting of mixed metal salts, of lithium and aluminum phosphates and sulfates, and combinations with metallic cations, such as magnesium, titanium, zinc, zirconium and gallium, to provide adequate Lewis acidity; organic or inorganic porosity promoters, such as polysaccharides; and agglomerates, such as clays, kaolin and metal oxides of the type M.sub.xO.sub.y, where; M=Al, Mg, Sr, Zr or Ti, and other metals of groups IA, IIA and IVB, x=1 or 2 and y=2 or 3, for the formation of particles. A process is disclosed for obtaining from the catalyst by the hydrolysis of aluminum lithium hydride with water and oxygenated solvent, such as an ether. The catalysts are used in batch reactor and continuous flow systems in reactions that require moderate Lewis acidity, such as refining, petrochemical and general chemistry, including the transesterification of glycerides to produce alkyl esters.